Melanoma/Skin Cancer News

To advance health equity, it is time to normalize the collection of sexual orientation and gender identity (SOGI) data in clinical practice and in health services research.

Standard cancer care may fail to adequately address the needs of LGBTQ+ individuals, who face substantial disparities in access to screening, treatment and outcomes.

More than a third of patients with solid tumors showed evidence of antitumor response after treatment with ADP-A2M4CD8, according to data presented at the virtual ESMO Congress.

Frailty and comorbidities were some of the patient-related factors that drove patients to choose a watchful waiting approach to basal cell carcinoma, according to a study.

The FDA granted priority review to relatlimab and nivolumab for treatment of unresectable or metastatic melanoma.

Patients with resected stage IIB or stage IIC melanoma who received adjuvant pembrolizumab demonstrated a 35% reduction in risk for disease recurrence or death, according to results of the randomized phase 3 KEYNOTE-716 study.

Cristina Puig-Saus, PhD, and Daniel S. Shin, MD, PhD, of UCLA Jonsson Comprehensive Cancer Center received a $1 million award from the U.S. Department of Defense for research into novel cell therapies for rare melanomas.

An expert panel has developed recommendations on best practices for managing clinically relevant immune-related adverse events associated with immune checkpoint inhibitor treatment.

CPT codes rather than ICD codes may be a more effective proxy to determine the actual number of skin cancers experienced by an individual patient, according to a study.

Patients with cancer had lower rates of SARS-CoV-2 infection and mortality after two doses vs. one dose of COVID-19 vaccines, according to study results from Centre Léon Bérard Cancer Center published in Annals of Oncology.